Pseudomyogenic hemangioendothelioma
Authors:
Jakub Šagát; Tereza Sokolová; Václav Stejskal
Authors‘ workplace:
Fingerlandův ústav patologie, Fakultní nemocnice Hradec Králové a Univerzita Karlova, Lékařská fakulta v Hradci Králové
Published in:
Čes.-slov. Patol., 62, 2026, No. 3, p. 212-215
Category:
Original Article
Overview
Pseudomyogenic hemangioendothelioma is a rare endothelial tumor with a tendency for local recurrence and rare metastasis. The tumor most commonly affects young adults, with a predilection for soft tissues of distal lower extremities, and often presents with multifocal growth. Histologically, tumor cells exhibit a morphology reminiscent of muscle differentiation and grow in sheets or fascicles without forming vascular structures. Therefore, immunohistochemical examination is essential to confirm the vascular origin, typically showing positivity for ERG, CD31, and cytokeratin. Among more recent markers, immunohistochemical detection of FOSB has been utilized. Based on two case reports, a 54-year-old man with a multifocal tumor in the arm and a 71-year-old woman with an intraosseous tumor, we highlight the typical morphological and immunohistochemical features of this entity. This is done to bring attention to its recognition and differential diagnosis, which primarily includes epithelioid sarcoma, epithelioid hemangioedothelioma, sarcomatoid carcinoma, inflammatory myofibroblastic tumor, myogenic tumors, and primary bone tumors, mainly osteoblastoma.
Keywords:
pseudomyogenic hemangioedothelioma – epithelioid-like hemangioendothelioma – vascular tumor – epitheloid sarcoma
Sources
1. Al-Qaderi A, Mansour AT. Pseudomyogenic hemangioendothelioma. Arch Pathol Lab Med 2018; 143(6): 763-767.
2. Hornick JL, Fletcher CDM. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 2011; 35(2): 190-201.
3. Sheng WQ, Wang J. Primary pseudomyogenic haemangioendothelioma of bone. Histopathology 2012; 61(6): 1219-1224.
4. Inyang A, Mertens F, Puls F, et al. Primary pseudomyogenic hemangioendothelioma of bone. Am J Surg Pathol 2016; 40(5): 587-598.
5. Sugita S, Hirano H, Kikuchi N, et al. Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics. Diagn Pathol 2016; 11(1): 75.
6. Hung YP, Fletcher CDM, Hornick JL. FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma. Am J Surg Pathol 2017; 41(5): 596-606.
7. Trombetta D, Magnusson L, von Steyern FV, Hornick JL, Fletcher CD, Mertens F. Translocation t(7;19)(q22;q13)−a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? Cancer Genet. 2011; 204(4): 211-215.
8. Walther C, Tayebwa J, Lilljebjörn H, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. Pathol 2014; 232(5): 534-540.
9. Agaram NP, Zhang L, Cotzia P, Antonescu CR. Expanding the spectrum of genetic alterations in pseudomyogenic hemangioendothelioma with recurrent novel ACTB-FOSB gene fusions. Am J Surg Pathol. 2018; 42(12): 1653-1661.
10. Billings SD, Folpe AL, Weiss SW. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol 2003; 27(1): 48-57.
11. Youssef R, Davis JL, Anderson WJ, et al. Pseudomyogenic hemangioendothelioma presenting as a penile lesion. Virchows Arch 2024; 485(6): 1157-1160.
12. Thway K, Jones RL, Noujaim J, Fisher C. Epithelioid sarcoma: diagnostic features and genetics. Adv Anat Pathol. 2016; 23(1): 41-49.
13. Miettinen M, Wang Z, Sarlomo-Rikala M, Abdullaev Z, Pack SD, Fetsch JF. ERG expression in epithelioid sarcoma: a diagnostic pitfall. Am J Surg Pathol. 2013; 37(10): 1580-1585.
14. Stacchiotti S, Miah AB, Frezza AM, et al. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open. 2021; 6(3): 100170.
15. Tsuchihashi K, Baba E. Epithelioid hemangioendothelioma — its history, clinical features, molecular biology and current therapy. Jpn J Clin Oncol. 2024; 54(7): 739-747.
16. Lam SW, Cleven AHG, Kroon HM, Briaire-de Bruijn IH, Szuhai K, Bovée JVMG. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Arch. 2020; 476(3): 455-463.
17. Kosemehmetoglu K, Rekhi B, Wakely PE, Pant V, Dervisoglu S, Aydingoz U. Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma of bone: Clinicopathologic features of 5 cases. Ann Diagn Pathol. 2019; 41 : 116-123.
18. Fittall MW, Mifsud W, Pillay N, et al. Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun. 2018; 9(1): 2150.
19. Choi JH. Inflammatory myofibroblastic tumor: an updated review. Cancers 2025;17(8):1327.
20. Doyle LA, Fletcher CDM. Metastasizing “benign” cutaneous fibrous histiocytoma: a clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2013; 37(4): 484-495.
21. Choi JH, Ro JY. Cutaneous spindle cell neoplasms: pattern-based diagnostic approach. Arch Pathol Lab Med. 2018; 142(8): 958-972.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
2026 Issue 3
-
All articles in this issue
- Léky indukované změny v histopatologii
- Setkání s každým člověkem je obohacující…
- MONITOR aneb nemělo by vám uniknout, že...
- Iatrogenic injury of the gastrointestinal tract
- Morphological aspects of drug-induced cutaneous reactions
- Drug induced and toxic liver injury
- Drug-Induced Nephropathies from the Pathologist‘s Perspective
- Immunotherapy Adverse Events in the Treatment of Solid Tumors
- Mature B-cell Non-Hodgkin Lymphomas in Children and Young Adults: The Same Diseases as in Adults or Distinct Entities?
- Pseudomyogenic hemangioendothelioma
- Czecho-Slovak Pathology
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue
- Drug induced and toxic liver injury
- Léky indukované změny v histopatologii
- Morphological aspects of drug-induced cutaneous reactions
- Setkání s každým člověkem je obohacující…